Tenon Medical, Inc. (TNON)
| Market Cap | 8.59M +9.5% |
| Revenue (ttm) | 3.94M +20.4% |
| Net Income | -12.56M |
| EPS | -1.70 |
| Shares Out | 11.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,247 |
| Open | 0.7600 |
| Previous Close | 0.7307 |
| Day's Range | 0.7600 - 0.7695 |
| 52-Week Range | 0.6410 - 2.4800 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About TNON
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive inferior-posterior approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along it... [Read more]
Financial Performance
In 2025, Tenon Medical's revenue was $3.94 million, an increase of 20.35% compared to the previous year's $3.28 million. Losses were -$12.56 million, -8.17% less than in 2024.
Financial StatementsNews
Tenon Medical, Inc. Sets Date for First Quarter 2026 Earnings
LOS GATOS, CA / ACCESS Newswire / May 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announ...
Tenon Medical Earnings Call Transcript: Q4 2025
Record 2025 revenue rose 20% year-over-year, with Q4 up 92% on strong adoption of Catamaran and SImmetry+. Gross margin improved to 69% in Q4, and new FDA clearance plus $7.15M in financing support growth plans for 2026.
Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results
~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~ ~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second H...
WallachBeth Capital Announces Closing of Tenon Medical, Inc Private Placement of Senior Original Issue Discount Convertible Notes Offering for Gross Proceeds of $4.3 Million
JERSEY CITY, N.J., March 12, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announces the closing of Tenon Medical, Inc. (NAS...
Tenon Medical Announces Closing of Private Placement of Senior Convertible Notes Offering for Gross Proceeds of $ 4.3 Million
LOS GATOS, CA / ACCESS Newswire / March 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders,...
Tenon Medical announces expansion of U.S. intellectual property portfolio
Tenon Medical (TNON) announced a strategic expansion of its U.S. intellectual property portfolio following receipt of Notices of Allowance from the United States Patent and Trademark Office, USPTO, fo...
Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion
Expanded Global Portfolio Enhances Competitive Position and Supports Long-Term Growth Strategy LOS GATOS, CA / ACCESS Newswire / February 18, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "...
Tenon Medical reaffirms Q4 revenue $1.45M-$1.48M, up 90% y/y
Reaffirms FY25 revenue view $3.91M-$3.94M, up 20% y/y.
Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected Revenues
Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over year Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year LOS GATOS...
Tenon Medical sees Q4 revenue $1.45M-$1.48M, up 90% y/y
Tenon Medical (TNON) issued a letter to shareholders from Steve Foster, President and CEO, which read in part, “2025 was marked by strong commercial execution as we advanced innovation and
Tenon Medical files to sell 5.43M shares of common stock for holders
06:05 EST Tenon Medical (TNON) files to sell 5.43M shares of common stock for holders
Tenon Medical announces completion of initial cases with SImmetry+ system
Tenon Medical (TNON) announced the completion of the first clinical procedures utilizing the Company’s new SImmetry+ SI Joint Fusion System. Ali Araghi, DO, Orthopedic Spine Surgeon in Phoenix, Arizon...
Tenon Medical Announces Successful Completion of Initial Cases with New SImmetry(R)+ SI Joint Fusion System
~ Procedures Completed in Various Spine Centers of Excellence Throughout the Country Including Florida, Arizona, Ohio, and Texas ~ ~ SImmetry+ combines 3D-printed titanium implants, a robust joint dec...
Tenon Medical price target lowered to $2.50 from $2.75 at Alliance Global
Alliance Global lowered the firm’s price target on Tenon Medical (TNON) to $2.50 from $2.75 and keeps a Buy rating on the shares. The firm’s revised target reflects lower forecasts
Tenon Medical Announces Closing of $2.85 Million At-The-Market PIPE Financing
LOS GATOS, CA / ACCESS Newswire / November 14, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorde...
Tenon Medical Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 32% year-over-year to $1.2 million, driven by record Catamaran procedures and initial SiVantage contributions. Gross margin improved to 66%, and the company ended the quarter with $3.4 million in cash, later raising $2.85 million more.
Tenon(R) Medical Reports Third Quarter 2025 Financial Results
~ Record revenue of $1.2 million, a 32% year-over-year increase, reflecting record volume in Catamaran® SI Joint Fusion System procedures and the addition of SImmetry® SI Joint Fusion Product Sales ~ ...
Tenon Medical prices 2.2M shares at $1.285 in PIPE financing
Tenon Medical (TNON) announced the pricing of an at-the-market private investment in public equity financing with several accredited investors for total gross proceeds of $2,850,000. Under the terms o...
Tenon Medical(R) Announces Pricing of At-The-Market PIPE Financing
~ Strategically Placed PIPE With Industry Supportive Investor Cohort ~ LOS GATOS, CA / ACCESS Newswire / November 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company tra...
Tenon Medical, Inc. Announces Timing of Third Quarter 2025 Financial Results
LOS GATOS, CA / ACCESS Newswire / November 3, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorder...
Tenon Medical announces 510(k) clearance for SImmerty+ SI Joint Fusion System
Tenon Medical (TNON) has received U.S. Food and Drug Administration 510(k) clearance for the SImmetry+ SI Joint Fusion System. The SImmetry+ System is indicated for sacroiliac joint fusion for conditi...
Tenon Medical(R) Announces FDA 510(k) Clearance for SImmetry(R)+ SI Joint Fusion System
~Clearance expands Company's competitive advantage of clinically proven, minimally invasive technologies to treat debilitating SI joint conditions from multiple surgical approaches~ ~SImmetry+'s New 3...
Tenon Medical announces Catamaran Mainsail study publication
Tenon Medical (TNON) announced the second interim analysis publication from its ongoing MAINSAIL study, a prospective, single-arm, multi-center, post-market clinical trial evaluating clinical and radi...
Tenon(R) Medical Announces Second Peer-Reviewed Catamaran Mainsail(TM) Study Publication, Underscores Robust and Sustainable Clinical Outcomes Out to 12 Months
~ Clinically Significant Patient Outcomes Demonstrate Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at 12-Month Analysis ~ ~ 83% of Patients ...
Tenon announces full market launch of Catamaran SE SI Joint Fusion System
Tenon Medical (TNON) announced the full commercial market launch of its new Catamaran SE SI Joint Fusion System. The Catamaran SE Fixation Device expands the Company’s implant portfolio, providing phy...